FY2024 EPS Estimates for Vincerx Pharma Lowered by Analyst

Vincerx Pharma, Inc. (NASDAQ:VINC) – Research analysts at Leerink Partnrs dropped their FY2024 earnings estimates for Vincerx Pharma in a report issued on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($0.50) for the year, down from their prior forecast of ($0.38). The consensus estimate for Vincerx Pharma’s current full-year earnings is ($0.38) per share. Leerink Partnrs also issued estimates for Vincerx Pharma’s Q4 2024 earnings at ($0.13) EPS and FY2025 earnings at ($0.32) EPS.

Vincerx Pharma (NASDAQ:VINC) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17).

Separately, Leerink Partners dropped their price objective on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Vincerx Pharma Stock Down 7.5 %

NASDAQ VINC opened at $0.30 on Friday. The company has a 50 day moving average of $0.52 and a 200-day moving average of $0.64. Vincerx Pharma has a 1-year low of $0.29 and a 1-year high of $9.37.

Institutional Trading of Vincerx Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace LLP increased its holdings in shares of Vincerx Pharma by 359.1% in the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock valued at $266,000 after purchasing an additional 256,967 shares in the last quarter. Armistice Capital LLC bought a new position in Vincerx Pharma in the second quarter valued at approximately $1,610,000. Finally, Vanguard Group Inc. boosted its stake in Vincerx Pharma by 29.9% in the first quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock valued at $3,375,000 after acquiring an additional 153,575 shares during the last quarter. Institutional investors and hedge funds own 44.02% of the company’s stock.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.